{"id":781267,"date":"2023-08-31T07:42:36","date_gmt":"2023-08-31T11:42:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-reports-fourth-quarter-and-full-fiscal-year-2023-results\/"},"modified":"2023-08-31T07:42:36","modified_gmt":"2023-08-31T11:42:36","slug":"lifecore-biomedical-reports-fourth-quarter-and-full-fiscal-year-2023-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lifecore-biomedical-reports-fourth-quarter-and-full-fiscal-year-2023-results\/","title":{"rendered":"Lifecore Biomedical Reports Fourth Quarter and Full Fiscal Year 2023 Results"},"content":{"rendered":"
\n

CHASKA, Minn., Aug. 31, 2023 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (Nasdaq: LFCR) (\u201cLifecore\u201d or the \u201cCompany\u201d), a fully integrated contract development and manufacturing organization (\u201cCDMO\u201d), reported results for the fiscal 2023 fourth quarter and full year ended May\u00a028, 2023.<\/p>\n

\n CEO COMMENTS:<\/strong>\n <\/p>\n

James G. Hall, President and Chief Executive Officer of Lifecore, commented, “We completed a very busy fourth quarter finalizing our transition to a stand-alone life sciences company with the final divestitures of the Curation Foods segment, strong growth in our development portfolio, and the comprehensive strategic refinancing and expanded supply agreement with our key customer Alcon. Our entire organization is now aligned toward a common goal of expanding Lifecore’s position as a leading, fully integrated CDMO that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials and injectable grade Hyaluronic Acid (“HA”).”<\/p>\n

Mr. Hall continued, “We advanced our development portfolio in the fiscal fourth quarter with the addition of five projects affiliated with five new customers, which demonstrates the impact that our expanded commercial strategy and targeted sales approach is having on our opportunity pipeline. Concurrently, we are preparing our organization for the significant anticipated growth embedded in our portfolio, both in terms of capacity and people. To that end, our multi-use fillers remain on track for delivery in the coming months which will allow us to double our theoretical filling capacity to approximately 45 million units and put Lifecore in a great position to meet market needs and optimize our production across our manufacturing footprint. We also invested in our HA fermentation capacity during the fourth quarter and are in the process of moving from a single-shift fermentation production staff to a full 24\/7 staffing model, which we expect will increase our sterile HA capacity by up to 50% by June 2024, allowing us to fulfill the increased HA volume orders associated with our expanded demand.”<\/p>\n

“Looking ahead to our fiscal 2024 first quarter, our commercial momentum has continued, and we will add several new projects to our development portfolio for the period ended August 27, 2023. We believe this activity will begin to meaningfully contribute to our financial performance in fiscal 2024 second quarter and to a greater degree in the second half of the fiscal year.”<\/p>\n

\n LIFECORE FISCAL <\/strong>
\n FOURTH<\/strong>
\n QUARTER 2023 FINANCIAL HIGHLIGHTS:<\/strong>\n <\/p>\n